Finally, delivering an anti-TRAIL antibody adsorbed onto the surface of PLGA and NLC NPs that rapidly and efficiently reaches the brain after intranasal administration, may represent an advantageous and easy tool for the non-invasive and effective treatment of AD. This evidence concerns the gene TNFSF10 and Alzheimer disease.